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Abstract
Purpose Adverse drug reactions (ADRs) have an appreciable impact on patients’ health. Little is known however about ADR
reporting in ambulatory care environments especially in low- and middle-income countries. Consequently, our aim was to
determine knowledge, attitudes and practices (KAP) among health care professionals (HCPs) towards ADR reporting in primary
health care (PHC) facilities in South Africa. The findings will be used to direct future activities.
Methods Descriptive, cross-sectional design using quantitative methodology among 8 public sector community health care
centres and 40 PHC clinics in the Tshwane Health District, Gauteng Province. A self-administered questionnaire was distributed
to 218 HCPs, including all key groups.
Results A total of 200 responses were received (91.7%). Although an appropriate attitude towards ADR reporting
existed, the actual frequency of ADR reporting was low (16.0%). Of the respondents, 60.5% did not know how to
report, where to report or when to report an ADR and 51.5% said the level of their clinical knowledge made it
difficult to decide whether or not an ADR had occurred. Over 97.5% stated they should be reporting ADRs with 89%
feeling that ADR reporting is a professional obligation and over 70% that ADR reporting should be compulsory. When
results were combined, the overall mean score in terms of positive or preferred practices for ADR reporting was 24.6%
with pharmacists having the highest scores.
Conclusion Under-reporting of ADRs with gaps in KAP was evident. There is a serious and urgent need for education and
training of HCPs on ADR reporting in South Africa.
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Introduction
Adverse drug reactions (ADRs) are a major public health
problem that causes increased mortality, morbidity and costs,
including increased hospital admissions and length of stay
[1–9]. Physicians, pharmacists, dentists and nurses are in a
position to play a key role in pharmacovigilance programmes;
however, under-reporting of ADRs is common across coun-
tries especially in low- and middle-income countries (LMICs)
[10–18].
Health care professionals (HCPs), especially in LMICs,
should work together to remove barriers to ADR reporting
across sectors and establish effective pharmacovigilance sys-
tems [15, 17, 19–24]. This includes physicians, pharmacists
and nurses in ambulatory care in LMICs including South
Africa [25–29]. Such activities should result in safety signals
being detected at an earlier stage, leading to better and quicker
decisions about medicine use. However, this cooperation
means improved notification and recording of ADRs in am-
bulatory care where the majority of patients receive their
medicines.
ADR spontaneous reporting is currently the basic method
for collecting information about adverse post-marketing risks
and events [17, 30]. Spontaneous reporting systems are inex-
pensive and simple to operate, and form the core of the global
World Health Organization (WHO) database [31]. Their
strength is connected to actual reporting rates of ADRs by
HCPs, recognising through appreciable under-reporting in
many countries [32–37].
Many factors are associated with ADR under-reporting
among HCPs, referred to as ‘the seven deadly sins’ of
pharmacovigilance [38]. These include a lack of knowledge
about the necessary forms, ignorance of the rules and proce-
dures and type of events that must be reported and lack of time
and inertia, as well as lack of education among all key stake-
holder groups [12, 16, 17, 19, 21, 23, 24, 37–40]. In addition,
currently only a limited number of African countries have
formal ADR reporting systems. Countries include Morocco,
South Africa, Tanzania, Tunisia, Zimbabwe, Ghana, Egypt,
Nigeria, Mozambique, Uganda and Togo, all of which are full
members of the WHO Programme for International Drug
Monitoring [41]. Progress has been hampered by lack of train-
ing and funding [42]. However, pharmacovigilance activities
should increase with 35 African countries now part of the
WHO Programme for International Drug Monitoring [41,
43]. The number of ADRs reported from African countries
is also growing which is encouraging, with, for instance,
South Africa reporting 28,609 individual cases by the end of
2015 [43]. However, more needs to be done. Implementation
of successful spontaneous reporting systems requires re-
sources of staff and systems. Concerns in LMICs include the
remote location of a number of ambulatory care clinics and/or
primary healthcare (PHC) clinics and poor telecommunication
services, as well as low numbers of HCPs and inadequate
training [44]. The knowledge of, attitudes towards and prac-
tices of spontaneous reporting may also differ at various levels
of health care systems [15, 16, 19, 24].
Concerns with the under-reporting of ADRs in South
Africa led to the establishment of a Pharmacovigilance
Committee within the previous Medicines Control Council
(MCC) of South Africa [45], providing direction on ADR
reporting [46]. The MCC has now been replaced by the
South African Health Products Regulatory Authority
(SAHPRA) [47, 48]. Post-marketing reporting of ADRs is a
legal requirement. All serious or suspected ADRs must be
reported to the regulatory authority by the medicine licence
holder or applicant within 15 days of receipt of such informa-
tion [46]. There are also initiatives among the provinces
(regions) to promote pharmacovigilance activities to increase
the number of ADR reports [49].
Between 2012 and 2017, pilot projects were rolled-out in
10 health districts in South Africa to evaluate various health
system strengthening interventions focused at the PHC level
[50], in preparation for the implementation of the National
Health Insurance (NHI) scheme for universal healthcare in-
cluding improved quality of care and services. One of these
districts was the Tshwane Health District in Pretoria, deliver-
ing PHC services through community health centres (CHCs)
incorporating PHC clinics as the first point of entry to
healthcare services. Health status reports, including ADRs,
are discussed at the Tshwane Health District Pharmaceutical
and Therapeutics Committee (PTC) meetings on a quarterly
basis. PTCs are now a formal requirement across sectors in
South Africa [51]. Over the 18-month period prior to this
study, very few ADRs were considered, which is a concern.
Actual numbers were not available due to poor record-
keeping.
To date, few published studies have determined which fac-
tors relate to under-reporting of ADRs among PHC facilities
especially in LMICs [15, 19]. This compares to multiple stud-
ies among hospitals including South Africa where there are
concerns with the lack of reporting of ADRs although this is
now being addressed [1, 3–5, 14, 16, 17, 52–57].
This is a critical concern given the high prevalence of both
infectious and non-communicable diseases across Africa
[58–64]. In addition, there are appreciable differences in pa-
tients with HIV in sub-Saharan Africa compared with western
countries, with a higher percentage being women, leading to
appreciable genetic differences between the populations [63,
65]. There are also a considerable number of patients with
concomitant infectious diseases, including HIV, alongside
NCDs in sub-Saharan Africa, impacting on potential ADRs
with patients likely to be on multiple medications [66, 67].
An overview of concerns regarding the lack of reporting of
ADRs at a secondary level hospital in South Africa has recent-
ly been published alongside potential ways to address this [16,
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52]. To the best of our knowledge, information about these
variables among PHC facilities in South Africa has not been
published. This omission is a concern given the number of
patients treated at public PHC facilities in the country, coupled
with ongoing initiatives to improve the care of patients with
chronic diseases [68]. This study was undertaken to determine
the current ADR reporting situation among PHC facilities in
Tshwane Health District. The findings could be used to design
and implement programmes to improve ADR reporting at
PHC facilities in the province and other sites and could also
be of interest to other African countries striving to improve
healthcare delivery.
Methods
Study design and setting
A descriptive, cross-sectional design used quantitative meth-
odology and a self-administered questionnaire. The study was
conducted among all 48 PHC facilities in the Tshwane Health
District (8 CHCs and 40 PHC clinics), situated in the Gauteng
Province of South Africa. This district was chosen as it was a
pilot area for the introduction of NHI.
In the public sector, approximately 80% of consultations at
the PHC level are with a professional nurse. PHC clinics are
smaller facilities, mainly staffed by nurses and sometimes a
visiting physician. A pharmacist will visit clinics once a
month and, at the time of the study, post-basic pharmacist
assistants (PBPAs) were being introduced into clinics’ staff
complement, working under the direct supervision of a phar-
macist. CHCs are larger facilities than clinics, staffed by a
multidisciplinary PHC team consisting of professional nurses,
physicians, a pharmacist and PBPAs. Some CHCs operate
24 h per day with staff rotating.
Study population and participants
The study population consisted of 475 HCPs (38 physicians,
317 professional nurses, 10 pharmacists and 110 PBPAs)
employed at the 48 PHC facilities in the Tshwane
Health District at the time of the study.
A combined sample size estimation of all HCP categories
was performed on nQuery Advisor, Release 7.0, considering
staff rotations, visiting staff and that all facilities are not equal-
ly staffed. It was estimated that with a combined sample size
of 212 respondents, a two-sided 95% confidence interval for
the percentage HCPs with satisfactory knowledge, attitude
and practices would be within ± 5% of the percentage that
would be calculated from the sample, assuming that 80% of
the respondents had satisfactory knowledge, attitudes and
practices.
Convenience sampling was employed. HCPs who were
available on the day of data collection and who complied with
the following inclusion criteria were approached:
& HCPs permanently employed by the Gauteng Department
of Health
& Registered pharmacists, professional nurses, physicians
and PBPAs
& Willingness to participate in the study
& Provision of written informed consent.
Data collection instrument and process
A self-administered, structured questionnaire was developed
based on previous practice experience among the co-authors,
discussions with experts and consideration of the literature
[69]. Two experts in the field of pharmacovigilance reviewed
the questionnaire for content validity; after which, it was test-
ed among 6 HCPs for feasibility. The questionnaire was sub-
sequently revised to improve its robustness to achieve appro-
priate outcomes (Appendix 1 in the Supplementary Material).
Potential participants at the clinics were approached by one
of the six community service pharmacists. The aim and objec-
tives of the study were explained to them and written consent
to participate was obtained (Appendices 2 and 3 in the
Supplementary Material). A total of 218 questionnaires were
distributed. The questionnaires were handed to participants for
anonymous completion in a private room. On completion,
respondents placed questionnaires in a sealed box to ensure
confidentiality of responses.
Data entry and analysis
Data were captured using Microsoft Excel™, checked for ac-
curacy and cleaned before analysis with SAS, release 9.2,
running under Microsoft Windows.
Responses were categorised according to knowledge, atti-
tudes and practices based on the questions included in the
questionnaire. Correct or preferred responses were subject to
frequency counts and percentages for each item as well as for
the respective HCP category.
An individual overall mean score (%) was calculated for
each participant according to their knowledge, attitudes and
practices, followed by an overall mean and median (%) score
for each HCP category. Mean (%) scores for the different
HCP categories were compared by analysis of variance
(ANOVA), followed by pairwise comparisons using the t test.
Statistical significance was set at p < 0.05. An overall mean
score (%) with a 95% confidence interval (CI) for all partici-
pants was also calculated for knowledge, attitudes and
practices.
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Ethical considerations
Ethical clearance for the study was obtained from the Medunsa
Research Ethics Committee of the University of Limpopo, now
Sefako Makgatho Health Sciences University, prior to the com-
mencement of the study (MREC/H270/2013). Permission to
conduct the study at the PHC facilities was obtained from the
Tshwane Research Committee and the Chief Director of the
Tshwane Health District. All participants provided written in-
formed consent.
Results
Demographic characteristics
Two hundred of the 218 distributed questionnaires were com-
pleted, giving a response rate of 91.7%. No questionnaires were
excluded from the analysis. One hundred and sixty-six (83%)
respondents were female with 73.0% employed at PHC
clinics and 27% at CHCs. Table 1 gives further details of re-
spondents’ professions.
Health care professionals’ knowledge of what should
be reported as ADRs
More than three-quarters of respondents understood the term
‘adverse drug reaction’ (75.6%) with 92.5% aware that ADRs
must be reported (Table 1). Over 90% were also aware of the
objectives of pharmacovigilance in the public sector. However,
only 57.5% were aware of an ADR reporting and monitoring
system in the district, only 33% where to find the forms and
only 9.0% where to submit them (Table 1). Table 1 also con-
tains data related to the need for reports for important treatment
options as well as the breakdowns by specific HCP groups.
The overall mean knowledge scores for all participants,
based on individual mean scores, are also presented in
Table 1. Medical practitioners (82.8%; p = 0.0174), pharma-
cists (91.4%; p = 0.0025) and professional nurses (84.0%;
p < 0.0001) scored significantly higher than PBPAs (72.2%).
The respondents showed reasonably good knowledge of
the type of adverse events that should be reported, ranging
from 65.5% for congenital anomaly to 89.5% for reaction to
a new medicine and a serious event (Fig. 1).
Attitudes towards adverse drug reaction reporting
Table 2 contains data related to the attitudes and importance of
ADR reporting. A high percentage (89.0%) agreed that
reporting ADRs is a professional obligation and that there
was a need for training. ADR reporting is also considered very
important in everyday work (63.0%).
Individual overall attitude scores (%) were calculated for
each HCP participant, based on positive or preferred re-
sponses, and then combined in group scores. The overall mean
positive or applicable attitude score was 63.3% (95%CI 60.7–
65.8%). The mean attitude scores of medical practitioners
(66.7%; p = 0.0055), pharmacists (73.9%; p = 0.0011) and
professional nurses (68.3%; p < 0.0001) were significantly
greater than those of PBPAs (55.2%).
The major factors which were perceived to discourage
ADR reporting are listed in Table 3. Nearly two-thirds of
participants (60.5%) did not know how to report, where to
report or when to report an ADR. Over half of the HCPs
(51.5%) said that the level of their clinical knowledge made
it difficult to decide whether or not an ADR had occurred.
Respondents’ perceptions of possible roles of HCPs in
responding to ADRs are contained in Fig. 2. Over 97% stated
that they should be reporting ADRswith over 92% stating that
they should try to prevent ADRs when selecting medicines to
treat their patients.
HCP current practice of ADR reporting
Table 4 shows that only 16.0% of HCPs surveyed had ever
reported a suspected ADR, although 65.0% said that ADR
forms were available in their facilities and only 12.0% knew
where the forms were kept.
In contrast to the 16.0% of respondents who stated that they
had reported an ADR, more than a third (36.5%) of respon-
dents said that they kept copies of the forms they submitted,
but only three could attach a copy of the completed form. This
anomaly casts doubts on their understanding of these two
questions. Only 17.0% of respondents indicated they had ever
received training on ADR reporting, more among pharmacists
than other HCPs (Table 4).
When all practice questions and statements for all HCPs
were combined, the overall mean score in terms of positive or
preferred practices for ADR reporting was 24.6% (95% CI
21.7–27.4%). The mean practice score for PBPAs (20.9%)
was significantly lower than the mean for pharmacists
(33.3%; p = 0.050), whilst not significantly different from
the mean practice scores of medical practitioners (21.7%)
and professional nurses (27.5%).
Based on the overall mean scores, pharmacists achieved the
highest ranking in terms of knowledge, attitudes and practice.
Although the differences were not statistically significant,
these findings would not have been out of place due to phar-
macists’ training focussing on medicines.
Discussion
Whilst a positive attitude to ADR reporting existed among
HCPs working at PHC facilities in our study, the actual
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practice of ADR reporting was poor, similar to studies in other
LMICs including India [57, 69–73], Pakistan [54] and
Romania [74].
Our results reflected a lack of awareness (57.5%) of HCPs
about the existence of an ADR reporting system (Table 1),
reflected by very few HCPs ever reporting an adverse event
Table 1 Knowledge of health care professionals on adverse drug reactions (ADRs) (n = 200)
Item Pharmacist
(n = 10)
Medical
practitioner
(n = 23)
Professional
nurse (n = 89)
Post-basic
pharmacist
assistant (n = 78)
Total (n = 200)
Number (%) of correct responses per health care professional category
Understanding the term ‘adverse drug reaction’ 10 (100%) 19 (82.6%) 66 (74.2%) 56 (71.8%) 151 (75.6%)
Know that ADRs must be reported 10 (100%) 18 (78.3%) 87 (97.8%) 70 (89.7%) 185 (92.5%)
Know of existence of an ADR reporting and
monitoring system in district
7 (70.0%) 12 (52.1%) 58 (65.2%) 38 (48.7%) 115 (57.5%)
Know where to find the form to complete
for reporting ADRs
6 (60.0%) 4 (17.4%) 33 (37%) 23 (29.5%) 66 (33.0%)
Know where the ADR reporting form must be submitted 3 (30.0%) 2 (8.7%) 7 (7.9%) 6 (7.7%) 18 (9.0%)
An event related to these
items must be
reported
Allopathic drugs 9 (90.0%) 15 (65.2%) 55 (61.8%) 40 (51.3%) 119 (59.5%)
Herbal drugs 9 (90.0%) 15 (65.2%) 56 (62.9%) 41 (52.6%) 121 (60.5%)
Traditional and
complementary medicine
8 (80.0%) 15 (65.2%) 65 (73.0%) 45 (57.7%) 133 (66.5%)
Blood products 8 (80.0%) 22 (95.7%) 76 (85.4%) 52 (66.7%) 158 (79.0%)
Biologicals 9 (90.0%) 18 (78.3%) 64 (73.0%) 47 (60.3%) 138 (69.0%)
Medical devices 10 (100%) 21 (91.3%) 79 (88.8%) 54 (69.2%) 164 (82.0%)
Vaccines 8 (80.0%) 22 (95.7%) 81 (91.0%) 61 (78.2%) 172 (86.0%)
Main objectives of
pharmacovigilance in
the public sector
Improve patient care and safety 10 (100%) 23 (100%) 86 (96.6%) 69 (88.5%) 188 (94.0%)
Improve public health and
safety
10 (100%) 23 (100%) 84 (94.4%) 68 (87.2%) 185 (92.5%)
Contribute to assessment of
risk/benefit of medicines
10 (100%) 22 (95.7%) 87 (97.8%) 66 (84.6%) 185 (92.5%)
Promote understanding,
education and clinical
training in field
9 (90.0%) 23 (100%) 84 (94.4%) 67 (85.9%) 183 (91.5%)
Ensure effective
communication
of ADR reporting to public
10 (100%) 20 (87.0%) 83 (93.3%) 68 (87.2%) 181 (90.5%)
Mean and median (%) knowledge score on ADRs per health care professional category
Mean % (standard deviation) 91.4 (12.3) 82.8 (14.7) 84.0 (17.0) 72.2 (22.0) 79.6* (19.6)
Median % (quartile 1–quartile 3) 95.2 (85.7–100) 85.7 (71.4–95.2) 90.0 (76.2–95.2) 76.2 (61.9–90.5) 85.7
(71.4–95.2)
*95% CI 76.9–82.3
89.5%
89.5%
82.0%
78.0%
76.5%
76.5%
65.5%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Reaction to a new drug
Serious event
Death of a patient due to a suspected interaction
Unusual event
Well recognised adverse reaction of a drug
Any suspected drug interaction
Congenital anomaly
% Health care professionals
Fig. 1 Percentage of health care
professionals with knowledge of
the type of events that should be
reported (n = 200)
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(16.0%) or contributed to the ADR monitoring system in the
district (7.0%) (Table 4), again similar to other LMICs including
secondary care facilities in South Africa [16, 17, 72, 75].
However, reporting rates in this study are appreciably lower than
seen in India where 47% of respondent physicians had reported
an ADR [71] and Malaysia where 51.9% of physicians and
pharmacists in PHC facilities had reported an ADR in the past
year [19].
Whilst the majority of HCPs surveyed (89.0%) felt that
ADR reporting is a professional obligation (Table 2) similar
to other countries [17, 19, 56, 71, 74, 76], they would be
encouraged to report ADRs if the reaction is serious
(89.5%), for a new product (89.5%) or unusual (78.0%)
(Fig. 1), similar to other studies [75–77]. However, 22
(11.0%) of HCPs were unaware of the professional obligation
to report ADRs (Table 2). Personal discussions and awareness
programmes should help to remove misconceptions and mod-
ify attitudes so that ADR reporting becomes an integral part of
clinical practice [19, 76, 78, 79]. The attitude of HCPs that a
single unreported case may not affect the ADR database
(19.0%) also needs to be challenged and changed.
Addressing this through education may well lead to enhanced
spontaneous reporting.
ADRs of herbal and traditional medicines are well known
[80–83]. However, only 60.5% of HCPs considered it neces-
sary to report events related to herbal drugs which is a concern
Table 2 Attitudes of health care professionals towards the reporting of adverse drug reactions (ADRs) (n = 200)
Item Pharmacist
(n = 10)
Medical
practitioner
(n = 23)
Professional
nurse (n = 89)
Post-basic pharmacist
assistant (n = 78)
Total positive
responses (n = 200)
Number (%) of positive responses per health care professional category
ADR reporting is necessary 10 (100%) 21 (91.0%) 84 (94.4%) 67 (85.9%) 182 (91.0%)
ADR reporting is a professional obligation 10 (100%) 18 (78.3%) 87 (97.8%) 63 (80.8%) 178 (89.0%)
Need for training on ADR reporting 7 (70.0%) 20 (87.0%) 78 (87.6%) 73 (93.6%) 178 (89.0%)
ADR reporting should be Voluntary 4 (40.0%) 3 (13.0%) 5 (5.6%) 8 (10.3%) 20 (10.0%)
Compulsory 6 (60.0%) 13 (56.5%) 76 (85.4%) 54 (69.2%) 149 (74.5%)
Remunerated 0 2 (8.7%) 2 (2.2%) 1 (1.3%) 5 (2.5%)
Health care worker’s role Preventing ADRs 9 (90.0%) 22 (95.7%) 83 (93.3%) 71 (91.0%) 185 (92.5%)
Detecting ADRs 10 (100%) 23 (100%) 85 (95.5%) 64 (82.1%) 182 (91.0%)
Managing ADRs 10 (100%) 23 (100%) 85 (95.5%) 63 (80.8%) 181 (90.5%)
Reporting ADRs 10 (100%) 22 (95.7%) 88 (98.9%) 75 (96.2%) 195 (97.5%)
The importance of
pharmacovigilance in
everyday work
Very important 5 (50.0%) 13 (56.5%) 57 (64.0%) 51 (65.4%) 126 (63.0%)
Important 5 (50.0%) 7 (30.4%) 21 (23.6%) 20 (25.6%) 53 (26.5%)
Slightly important 0 0 0 0 0
Not important at all 0 0 0 0 0
Mean and median (%) attitude score on ADRs per health care professional category
Mean % (standard deviation) 73.9 (18.5) 66.7 (15.5) 68.3 (17.8) 55.2 (16.9) 63.3* (18.3)
Median % (quartile 1–quartile 3) 77.8 (66.7–83.3) 66.7 (61.1–83.3) 72.2 (55.6–83.3) 50.0 (44.4–66.7) 63.9 (50.0–77.8)
*95% CI 60.7–65.83
Table 3 Major factors which
discouraged reporting of adverse
drug reactions (ADRs) (n = 200)
Factors discouraging ADR reporting Number (%) of HCPs
(n = 200)
A single unreported case may not affect the ADR data base 38 (19.0%)
Non-remuneration for reporting 47 (23.5%)
Lack of confidence to discuss the ADRs with other colleagues 56 (28.0%)
Concern that reporting may generate extra work 67 (33.5%)
Lack of time to actively look for ADRs whilst at work 79 (39.5%)
Lack of time to complete a report 88 (44.0%)
Concern that the report may be incorrect 93 (46.5%)
Level of clinical knowledge makes it difficult to decide whether or
not an ADR has occurred
103 (51.5%)
Do not know how to report, where to report and when to report 121 (60.5%)
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(Table 1). This is important in South Africa and across Africa
since many such remedies are currently being used [84–86]
and there is appropriate legislation to address this [87].
However, this attitude may reflect a general reluctance among
the population to admit to seeking traditional remedies al-
though such practices may be common especially among rural
black households in South Africa [88].
A number of factors impacted negatively on the willingness
to report ADRs of which ‘Do not know how to report, where to
report and when to report’ (60.5%) was the most prominent
(Table 3). These findings suggest that under-reporting of
ADRs is associated with gaps in knowledge, attitudes and prac-
tices, similar to other studies including hospital-based studies
[17–19, 23, 72, 74, 76]. Concerns with lack of knowledge may
reflect a spontaneous reporting rate of only 16.0% (Table 4),
similar to other reported studies [72, 75]. Another concern was
that only 12.0% of HCPs knew where the ADR forms were
kept (Table 4). These joint findings again suggest a serious and
urgent need for appropriate education and training, from iden-
tification to reporting, which should improve spontaneous
reporting [19, 72, 76, 89–91]. We have seen the successful
implementation of a pharmacist-directed improvement plan to
enhance ADR reporting in secondary care in South Africa [52].
Whether a similar approach would be successful over a number
of widespread PHC facilities remains to be seen. However, such
approaches are being tried in other countries [19, 72, 78], and
92.5% 91.0% 90.5%
97.5%
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Fig. 2 Health care professionals’
perceived roles in ADR reporting
(n = 200)
Table 4 Practice of health care professionals in adverse drug reaction (ADR) reporting (n = 200)
Item Pharmacist
(n = 10)
Medical
practitioner
(n = 23)
Professional
nurse (n = 89)
Post-basic
pharmacist
assistant (n = 78)
Total correct
responses
(n = 200)
Number (%) correct responses per health care professional category
Have you ever reported any
suspected ADR?
Yes 4 (40.0%) 6 (26.1%) 12 (13.5%) 10 (12.8%) 32 (16.0%)
Have you reported any suspected
ADR to the ADR reporting and
monitoring system in your district?
Yes 1 (10.0%) 3 (13.0%) 4 (4.5%) 6 (7.7%) 14 (7.0%)
Do you have the adverse reporting
form available in your facility?
Yes 7 (70.0%) 10 (43.5%) 70 (78.7%) 43 (55.0%) 130 (65.0%)
Where are the ADR forms kept in
your facility?
Pharmacy/managers
office
3 (30.0%) 3 (13.0%) 13 (14.6%) 5 (2.5%) 19 (12.0%)
Copies of the submitted ADR forms
are kept
Yes 2 (20.0%) 6 (26.1%) 37 (41.6%) 28 (35.9%) 73 (36.5%)
Copy of form attached to
questionnaire
Yes 0 0 2 (2.2%) 1 (1.3%) 3 (1.5%)
Training received on ADR reporting Yes 4 (40.0%) 4 (17.4%) 18 (20.2%) 8 (10.3%) 34 (17.0%)
Mean and median (%) practice score on ADRs per health care professional category
Mean % (standard deviation) 33.3 (31.4) 21.7 (24.3) 27.5 (18.0) 20.9 (20.4) 24.6* (20.7)
Median % (quartile 1–quartile 3) 25.0 (0.0–66.7) 16.7 (0.0–33.3) 33.3 (16.7–33.3) 16.7 (0.0–33.0) 16.7 (8.3–33.3)
*95% CI 21.7–27.4
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wewill be following the findings with interest. In themeantime,
all HCPs in South Africa should be encouraged to report
suspected ADRs irrespective of the level of association with
the possible cause [36]. Reporting whether known, unknown,
common, uncommon, serious or mild ADR, even with
established medicines, should be encouraged. Training in
pharmacovigilance should also be included in the core curricu-
lum of all HCPs following government initiatives [47], helped
by the introduction of a new reporting form [48, 68]. Provision
is also being made for a mobile electronic version (App), which
would include an acknowledgement of a receipt sent to the
reporter to address concerns. These initiatives will be investi-
gated in future studies for their impact.
In addition, SAHPRA is in the process of strengthening its
vigilance and post-marketing surveillance programme, includ-
ing the development of a communication strategy to support
improved external stakeholder interactions and relations.
Providing relevant and user-friendly feedback to stakeholders,
particularly health professionals and the public, should start to
address previous concerns [47].
We are aware of a number of limitations with this study
such as including only one district and an unequal distribution
of participants from the different HCP categories. For in-
stance, there was low participation (28%) from nurses. We
are not sure why but possible reasons could include being
reluctant to participate, being too busy or being on night duty
at the 24-h CHCs. However, all pharmacists as well as a high
percentage of PBPAs (71%) and physicians (60%) took part.
In addition, qualitative research methodologies would have
provided a more in-depth understanding. Future research is
planned to address these concerns. Despite these limitations,
we believe our findings are robust and provide direction for
the future as the authorities strive to improve the use of med-
icines in ambulatory care.
Conclusion
Our findings strongly suggest that under-reporting of ADRs is
associated with gaps in knowledge, attitudes and practices
among ambulatory care HCPs in South Africa. Consequently,
there is a great need to create awareness about ADRs and to
promote the reporting of ADRs amongHCPs. This is especially
important given the rising burden of non-communicable dis-
eases in South Africa along with infectious diseases. Training
sessions should help, augmented by structured surveillance and
electronic methods of data handling, analysis and the genera-
tion of ADR reports. In addition, ADR reporting must be seen
as an integral part of undergraduate training and the clinical
activities of all ambulatory care HCPs. We will be monitoring
this process in the future.
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